Treatment Action Group (TAG) applauds the legal actions undertaken by our colleagues from the Delhi Network of Positive People (DNP+) and tuberculosis (TB) survivor and activist Ganesh Acharya of Mumbai, with support from the Third World Network (TWN), contesting two patent applications on combinations of two decades-old TB medicines filed in India by French pharmaceutical company Sanofi.
Vote Your ConSCIENCE: Elevating Health Justice in the 2020 Elections. 2020 marks the eighth U.S. presidential election cycle since Treatment Action Group’s founding in 1992. A hallmark of our activism has been to prepare for each presidential and congressional election cycle strategically, to ensure that whoever is elected, and whoever controls the House and the Senate, is informed about the best scientifically grounded research and policy and research programs.
To encourage more equitable access to new and repurposed TB drugs, TAG signed on to letters of support for the inclusion of rifapentine, bedaquiline, delamanid, and linezolid on the WHO's Model List of Essential Medicines. The 20th Expert Committee on the Selection and Use of Essential Medicines will review drug applications and public comments in April 2015.
TAG and the TB CAB signed on to open letters to several manufacturers of U.S. Food and Drug Administration (FDA)-approved generic linezolid, including Pfizer, Teva, Glenmark, Alkem, Amneal, Macleods, Apotex, Hetero, and Sanofi urging the companies to register their respective linezolid products with the Medicines Control Council (MCC) in South Africa. Registration of additional linezolid products will address the existing effective market monopoly and extremely high prices that prevent linezolid from being offered to all patients who could benefit from its use in South Africa and countries like Swaziland that rely on the South African regulatory approval system. The co-signatories asked that following registration, companies provide linezolid at the price currently offered to country programs through the Global Drug Facility (GDF).
TAG and other U.S.-based NGOs and civil society groups sent several appeals to legislators to prioritize tuberculosis (TB) in plans for fiscal year 2017 in line with the White House’s recently released National Action Plan for Combating Multidrug-Resistant Tuberculosis. Letters to three key House and Senate subcommittees—the Labor, Health and Human Services, Education, and Related Agencies Subcommittee, the Defense Subcommittee, and the Subcommittee on State, Foreign Operations, and Related Programs.
The high cost of GeneXpert tests for tuberculosis (TB) leaves open a critical gap in the diagnosis of TB and fails to consider volume of sales and public investments in the development of GeneXpert.
October 31, 2019 — Civil society and community-based organizations issued this letter welcoming the availability of lower-priced rifapentine, which is an essential medicine for preventing TB. However, while all the organizations agree that this discount is a step forward, they're…
Presented at the 50th Union World Conference on Lung Health, an analysis by Treatment Action Group (TAG) finds that total public expenditures on the development of bedaquiline –– an important medicine for drug-resistant tuberculosis (DR-TB) –– far exceed those of the originator company, Johnson & Johnson.
TAG presented an analysis at the 50th Union World Conference on Lung Health, which found that that total public expenditures on the development of bedaquiline, an important medicine for drug-resistant tuberculosis, far exceed those of Johnson & Johnson, the originator company.
Civil society and community-based organizations issued this statement welcoming the availability of lower-priced rifapentine, which is an essential medicine for preventing TB.